Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOPE: High-Dose Prophylactic Gabapentin to Prevent Opioid Use for Oral Mucositis Pain During Head and Neck Chemoradiotherapy
NCT06992427Phase 3Recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jun 2025
- Primary completion
- Aug 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gabapentin in oral mucositis (OM), sponsored by Cancer and Leukemia Group B. Started Jun 2025; status: recruiting.
02
Drugs
gabapentin
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT06992427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06992427.